Replies to post #4933244 on BB's Stock Haven

[BlazingStocks]

$NBIO - "The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients," stated Dr. Mini Gill who presented for the Company.
https://finance.yahoo.com/news/nascent-biotech-phase-clinical-data-120000403.html